2013 ACR/ARHP Annual Meeting

October 25-30, 2013. San Diego, CA.

View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1420

Induction Therapy With Adalimumab On Top Of An Aggressive Treat-To-Target Strategy With Methotrexate and Intraarticular Corticosteroid Reduces Radiographic Erosive Progression In Early Rheumatoid Arthritis, Even After Withdrawal Of Adalimumab. Results Of a 2-Year Trial (OPERA)
Abstract Number: 491

Infection Risk Among Patients Receiving Concurrent Denosumab and Biologic Or Non-Biologic DMARD Therapy: An Analysis Of The Consortium Of Rheumatology Researchers Of North America (CORRONA) Registry
Abstract Number: 1507

Infection Risk in Ankylosing Spondylitis: Results From a Longitudinal Observational Cohort
Abstract Number: 2166

Infection Risk With Tumor Necrosis Factor Inhibitor Use In Polyarticular Juvenile Idiopathic Arthritis
Abstract Number: 1675

Infections Requiring Or Acquired During Hospitalizations In Patients With Giant Cell Arteritis – a Population Based Retrospective Cohort Study
Abstract Number: 2016

Inflamamatory Myositis-Increased Incidence In Fire Department Of New York Firefighters After World Trade Center Exposure
Abstract Number: 2841

Inflammation and Structural Progression In The Sacroiliac Joints Of Patients With Axial Spa Treated With Adalimumab Or Placebo As Assessed By The Berlin and The Spondyloarthritis Research Consortium Of Canada MRI Methods
Abstract Number: 1539

Inflammation In The Posterior Elements Of The Spine Is Infrequent In Patients With Recent Onset Axial Spondyloarthritis, Especially If No Inflammation In The Vertebral Bodies Is Observed
Abstract Number: 2523

Inflammatory Arthritis Activity During Pregnancy In Systemic Lupus Erythematosus
Abstract Number: 268

Inflammatory Bowel Disease In Juvenile Idiopathic Arthritis Patients Upon Biologics
Abstract Number: 358

Inflammatory Burden Predicts Carotid Plaque Progression and Subsequent Cardiovascular Events In Rheumatoid Arthritis: The 2-Year Prospective Cohort Study
Abstract Number: 371

Inflammatory Cell Infiltrates In The Heart Of Patients With Coronary Artery Disease With and Without Inflammatory Rheumatic Disease: A Biopsy Study
Abstract Number: 764

Inflammatory Disease Due To Dysregulated Nuclear Factor-κB Activation and Impaired Type I Interferon Response Resulting From a De Novo Human NEMO Hypomorphic Mutation
Abstract Number: 2077

Inflammatory Lung Disease a Potential Risk Factor For Onset Of Inflammatory Myopathies
Abstract Number: 2626

Infliximab For Sight-Threatening and Refractory Uveitis Of Behcet’s Syndrome

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].